Physician profile
David B Jack
NPI 1255434296
$6,086.03
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $948 · 2021: $1,252 · 2022: $2,783.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,571.20 | 2020-2022 | |
| Amgen INC. | $359.79 | 2019-2022 | |
| Novo Nordisk INC | $304.60 | 2019-2022 | |
| Astellas Pharma US INC | $247.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.28 | 2019-2022 | |
| Lilly USA, LLC | $185.84 | 2019-2021 | |
| Boston Scientific Corporation | $170.63 | 2019-2022 | |
| Amarin Pharma, INC. | $165.12 | 2019-2021 | |
| Abbvie INC. | $156.07 | 2019-2022 | |
| Horizon Therapeutics Plc | $150.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $146.29 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $136.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.14 | 2019-2022 | |
| Allergan, INC. | $112.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $98.23 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $95.67 | 2020 | |
| Pfizer INC. | $94.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $78.83 | 2019-2022 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Abbott Laboratories | $59.29 | 2019-2021 | |
| Dexcom, INC. | $54.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $51.03 | 2019-2021 | |
| Biogen, INC. | $48.35 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $36.62 | 2020-2021 | |
| Mannkind Corporation | $36.21 | 2021 | |
| Sunovion Pharmaceuticals INC. | $34.73 | 2020-2021 | |
| Insulet Corporation | $31.64 | 2020 | |
| Merck Sharp & Dohme LLC | $28.77 | 2021 | |
| Nevro Corp. | $27.65 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.37 | 2021 | |
| Eisai INC. | $27.32 | 2021 | |
| Janssen Biotech, INC. | $20.43 | 2019 | |
| Gilead Sciences, INC. | $18.65 | 2019 | |
| Upsher-Smith Laboratories LLC | $18.25 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.86 | 2019 | |
| Antares Pharma, INC. | $16.14 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.77 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.48 | 2019 | |
| Dynavax Technologies Corporation | $12.66 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$15,318.55 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.